Upgrade to SI Premium - Free Trial

UBS Reiterates Buy Rating on Eli Lilly (LLY) on Deal to Acquire ATAI

July 17, 2026 9:13 AM
UBS analyst Michael Yee reiterated a Buy rating and $1,425.00 price target on Eli Lilly (NYSE: LLY).The analyst commented, "Eli ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments